Case Study: GLP Compliance Audit to Evaluate Risks and Quality Gaps in a Toxicology Program

A biopharmaceutical sponsor engaged PAR Clinical for an independent, on-site GLP compliance audit of a central laboratory running two parallel 12-week topical toxicity studies. The engagement was designed to give the sponsor an unbiased, third-party view of the CRO's day-to-day quality practices, separate from the CRO's own internal assurances.

On paper, the CRO's quality system appeared mature and well-documented. In practice, deviation logs and study amendment histories raised concerns about consistency across the two studies. The sponsor needed to understand whether documentation and process gaps represented isolated lapses or systemic weaknesses in the CRO's quality program, and whether those weaknesses posed risk to data integrity, study validity, or regulatory submission readiness.

PAR Clinical structured the audit around four core workstreams, moving from facility-level observation to targeted stakeholder engagement:

1.     Full Facility Tour. A complete walkthrough of the laboratory, from test item receipt through sample archiving, assessing workflows, equipment, and operational controls at each stage of the study lifecycle.

2.     Documentation Deep-Dive. A detailed review of study plans, protocol amendments, raw data records, and staff training files to evaluate completeness, consistency, and adherence to Good Documentation Practice (GDP).

3.     Computerized System Review. Validation of audit trails and an assessment of the laboratory's IT framework for compliance with data integrity and electronic records requirements.

4.     Stakeholder Interviews. Structured interviews with study directors, quality assurance personnel, and laboratory management to corroborate documentary findings and surface process issues not visible in written records alone.

The audit identified four areas of concern that, taken together, pointed to systemic rather than isolated quality gaps:

•      Study Plan Amendment Controls. Documentation and approval of study plan amendments were inconsistent across both studies, indicating a lack of standardized change-control practice.

•      Documentation Integrity. Good Documentation Practice gaps were identified, including missing dates, unauthorized corrections, and the use of outdated templates.

•      Raw Data Management. Traceability gaps in raw data handling were found to have a direct impact on study validity.

•      Deviation Trending. An elevated rate of recurring deviations pointed to underlying, systemic process failures rather than one-off errors.

Based on these findings, PAR Clinical established a detailed corrective action plan for the sponsor. The plan outlined the specific deficiencies identified during the audit and provided a structured basis for requiring the CRO to develop robust CAPA (Corrective and Preventive Action) responses, including root cause analysis and defined resolution timelines for each finding.

Early Warning

The audit identified critical quality gaps before final study reports were issued, giving the sponsor time to make proactive corrections and avoid costly regulatory delays.

Negotiation Leverage

The audit findings gave the sponsor the standing to require robust CAPA plans from the CRO, complete with root cause analysis and defined timelines for resolution.

Regulatory Confidence

A clear understanding of the systemic gaps helped the sponsor prepare targeted, informed questions ahead of regulatory inspections, strengthening overall submission readiness.

Vendor Oversight

The engagement demonstrated the strategic value of routine, second-party GLP audits, and established a replicable vendor oversight model within the sponsor's broader quality program.

This engagement illustrates the value of independent, on-site GLP audits as a proactive risk management tool. By surfacing systemic documentation, traceability, and change-control gaps before final study reports were finalized, PAR Clinical enabled the sponsor to act early, strengthen its oversight of the CRO, and enter regulatory review with greater confidence in its data integrity and compliance posture.

At PAR Clinical, we are committed to continuous process improvement and shaping the drug development industry through rigorous, knowledge based approach. Founded as a strategic clinical development ecosystem facilitator, PAR Clinical partners with healthcare organizations to design forward looking strategies that ultimately improve patient outcomes.

 We build resilient, scalable operational ecosystems - creating value and safeguarding business continuiyt for the future. As a strategic consulting partner and fractional resource facilitator, we deliver tailored operational solutions that align with each client's goals, enabling them to achieve meaningful and sustainable organizational success.

To learn more about our services, please visit us at www.parclinical.com or schedule a 30-minute call with sidparulkar@parclinical.com.